

*See E1
31
cont* wherein said cysteine residues are identified in SEQ ID NO:4.

REMARKS

Claim 4 has been amended to more clearly claim the invention and to correct the omission of a period. A VERSION WITH MARKINGS TO SHOW CHANGES MADE is attached in which deletions are shown within brackets and additions are underlined.

In the Notice from the Office, the Examiner objects to the omission of the reference to a SEQ ID NO: identifier in Claim 4. This reference has now been added.

Conclusion

In light of the Applicant's amendments to the claims, it is respectfully submitted that the present application is in condition for allowance. Should the Examiner have any remaining concerns which might prevent the prompt allowance of the application, the Examiner is respectfully invited to contact the undersigned at the telephone number appearing below.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 18 April 2001

By: Daniel Altman

Daniel E. Altman
Registration No. 34,115
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(949) 760-0404

VERSION WITH MARKINGS TO SHOW CHANGES MADE

4. **(Amended Four Times)** The isolated polypeptide of Claim [3] 1, wherein said peptide has at least one pair of disulfide bonded cysteine residues selected from the group consisting of:

- (i) Cys₇₁ - Cys₁₈₉; and
- (ii) Cys₂₅₇ - Cys₂₇₀;
- (iii) Cys₂₅₉ - Cys₂₇₀;
- (iv) Cys₃₀₆ - Cys₃₂₂; and
- (v) Cys₃₆₂ - Cys₃₆₅;

wherein said cysteine residues are identified in SEQ ID NO:4..